Skip to main content
SpringerLink
Log in

Receptor PET/CT Imaging of Neuroendocrine Tumors

  • Chapter
Book cover PET in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 170))

Abstract

This chapter is dedicated to Gustav Hör, Professor Emeritus and former Director of the Department of Nuclear Medicine, University of Frankfurt/Main, on the occasion of his 75th birthday.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G (1998) Limited value of fluorine-18 fluo-rodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79–83

    Article  PubMed  CAS  Google Scholar 

  • Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Lang-strom B, Oberg K (1995) Pancreatic neuroendocrinetumors: diagnosis with PET. Radiology 195:333–337

    PubMed  CAS  Google Scholar 

  • Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW (2001) 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42:213–221

    PubMed  CAS  Google Scholar 

  • Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H (2007) Are radiogallium-labelled DOTA-conjugated somatostatin superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982–993

    Article  PubMed  CAS  Google Scholar 

  • Baum RP, Hofmann M (2004) Nuklearmedizinische Diagnostik neuroendocriner tumoren. Onkologe 10:598–610

    Google Scholar 

  • Baum RP, Prasad V (2007) Molecular imaging of neuro-endocrine tumors using Ga-68 DOTA-NOC receptor PET/CT semiquantitative analyses after 1,257 studies (EPOS). European Congress of Radiology 2007, Vienna, Austria

    Google Scholar 

  • Baylin SB, Abeloff MD, Goodwin G, Carney DN, Gazdar AF (1980) Activities of L-dopa decarboxylase and diamine oxidase (histaminase) in human lung cancers and decarboxylase as a marker for small (oat) cell cancer in cell culture. Cancer Res 40:1990–1994

    PubMed  CAS  Google Scholar 

  • Becherer A, Szabo M, Karanikas G, Wunderbaidinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K (2004) Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 45:1161–1167

    PubMed  CAS  Google Scholar 

  • Behe M, Becker W, Gotthardt M, Angerstein C, Behr TM (2003) Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled mini-gastrin derivatives. Eur J Nucl Med Mol Imaging 30:1140–1146

    Article  PubMed  CAS  Google Scholar 

  • Behr TM, Behe MP (2002) Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystoki-nin-B receptor-expressing malignancies. Semin Nucl Med 32:97–109

    Article  PubMed  Google Scholar 

  • Behr TM, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S, Raue F, Becker W (1998) Targeting of chole-cystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25:424–430

    Article  PubMed  CAS  Google Scholar 

  • Behr TM, Behe M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W (1999) Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 5:3124s–3138s

    PubMed  CAS  Google Scholar 

  • Behr TM, Gotthardt M, Barth A, Behe M (2001) Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189–200

    PubMed  CAS  Google Scholar 

  • Berger CL, de Bustros A, Roos BA, Leong SS, Mendelsohn G, Gesell MS, Baylin SB (1984) Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression. J Clin Endocrinol Metab 59:338–343

    PubMed  CAS  Google Scholar 

  • Berglund AS, Hulthen UL, Manhem P, Thorsson O, Wollmer P, Tornquist C (2001) Metaiodobenzylgua-nidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J Intern Med 249:247–251

    Article  PubMed  CAS  Google Scholar 

  • Blum J, Handmaker H, Lister-James J, Rinne N (2000) A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 117:1232–1238

    Article  PubMed  CAS  Google Scholar 

  • Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A (2001) Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 12 [Suppl 2]:S51–S61

    Article  Google Scholar 

  • Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E (2004) Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 48:150–163

    PubMed  CAS  Google Scholar 

  • Breeman WA, De Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME, Hofland LJ, Visser TJ, Krenning EP (1999) Pre-clinical evaluation of [(111)In-DTPA-Pro(l), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 83:657–663

    Article  PubMed  CAS  Google Scholar 

  • Castellani MR, Chiti A, Seregni E, Bombardieri E (2000) Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 44:77–87

    PubMed  CAS  Google Scholar 

  • De Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Behe M, Powell P, Macke HR (1997) Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24:368–371

    Article  PubMed  Google Scholar 

  • Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ (2000) 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 41:1114–1119

    PubMed  CAS  Google Scholar 

  • Deutsch E (1993) Clinical PET: its time has come? J Nucl Med 34:1132–1133

    PubMed  CAS  Google Scholar 

  • Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F (2001) Fluorine-18 fluorode-oxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676

    Article  PubMed  CAS  Google Scholar 

  • Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B (2000) Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 44:68–76

    PubMed  CAS  Google Scholar 

  • Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG (1988) Expression of neuroendocrine cell markers L-dopa decar-boxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078–4082

    PubMed  CAS  Google Scholar 

  • Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR (2005) Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11:1136–1145

    PubMed  CAS  Google Scholar 

  • Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Macke HR, Reubi JC (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sei USA 103:16436–16441

    Article  CAS  Google Scholar 

  • Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Macke HR, Hofmann M, Debus J, Haberkorn U (2001) PET imaging of somatostatin receptors using [68GA]DOTA-D-Phel-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 42:1053–1056

    PubMed  CAS  Google Scholar 

  • Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Macke HR, Eisenhut M, Haberkorn U (2004) Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET. Eur J Nucl Med Mol Imaging 31:466

    Article  PubMed  Google Scholar 

  • Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Macke HR, Eisenhut M, Debus J, Haberkorn U (2005) Characterization of Ga-DOTA-D-Phe1Tyr33-octreotide kinetics in patients with meningiomas. J Nucl Med 46:763–769

    PubMed  CAS  Google Scholar 

  • Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP (2002) Pheochromocytomas: detection with 18F DOPA whole body PET: initial results. Radiology 222:507–512

    Article  PubMed  Google Scholar 

  • Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751–1757

    Article  PubMed  CAS  Google Scholar 

  • Jacob T, Grahek D, Younsi N, Kerrou K, Aide N, Montravers F, Balogova S, Colombet C, De Beco V, Talbot JN (2003) Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging 30:1266–1269

    Article  PubMed  CAS  Google Scholar 

  • Jensen RT (2005) Endocrine tumors of the gastrointestinal tract and pancreas. In: Kasper DL, Fauci AS, Longo DL et al. (eds) Harrison’s principles of internal medicine. McGraw-Hill, New York, pp 2221–2231

    Google Scholar 

  • Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuro-endocrine tumors. Endocr Rev 25:458–511

    Article  PubMed  CAS  Google Scholar 

  • Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC (1989) Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30:481–489

    PubMed  CAS  Google Scholar 

  • Koukouraki S, Strauss L, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A (2006) Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neu-roendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33:460–466

    Article  PubMed  CAS  Google Scholar 

  • Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [nlIn]-DTPAOC SPECT. First results in patients with neu-roendocrine tumors. Mol Imaging Biol 5:42–48

    Article  PubMed  Google Scholar 

  • Krenning EP, Bakker WH, Breeman WA, Köper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242–244

    Article  PubMed  CAS  Google Scholar 

  • Krenning EP, Bakker WH, Lamberts SW (1990) Receptor scintigraphy with somatostatin analog in oncology. Ned Tijdschr Geneeskd 134:1077–1080

    PubMed  CAS  Google Scholar 

  • Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ et al (1992) Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-l-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 33:652–658

    PubMed  CAS  Google Scholar 

  • Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC et al (1993) Somatostatin receptor scin-tigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731

    Article  PubMed  CAS  Google Scholar 

  • Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M (2004) Peptide receptor radio-nuclide therapy. Ann N Y Acad Sci 1014:234–245

    Article  PubMed  CAS  Google Scholar 

  • Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP (1994) The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 21:1106–1113

    Article  PubMed  CAS  Google Scholar 

  • Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M, Reubi JC, Krenning EP (2000) Cholecystokinin receptor imaging using an octapep-tide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 27:1312–1317

    Article  PubMed  CAS  Google Scholar 

  • Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP (2001) [177Lu-DOTAOTyr3]octreotate: comparison with [mIn-DTPAo]octreotide in patients. Eur J Nucl Med 28:1319–1325

    Article  PubMed  CAS  Google Scholar 

  • Lebtahi R, Le Cloirec J, Houzard C, Daou D, Sobhani I, Sassolas G, Mignon M, Bourguet P, Le Guludec D (2002) Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with lllln-pentetreo-tide scintigraphy. J Nucl Med 43:889–895

    PubMed  CAS  Google Scholar 

  • Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP, Anderson CJ (1999) Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 5:3608–3616

    PubMed  CAS  Google Scholar 

  • Li S, Beheshti M (2005) The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets 5:139–148

    Article  PubMed  CAS  Google Scholar 

  • Maecke HR, Hofmann M, Haberkorn U (2005) (68)Ga-labeled peptides in tumor imaging. J Nucl Med 46 [Suppl 1]:172S–178S

    Google Scholar 

  • Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M (2006) Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [mIn]DTPA-octreo-tide. J Nucl Med 47:566–573

    PubMed  Google Scholar 

  • Moody TW, Hill JM, Jensen RT (2003) VIP as a trophic factor in the CNS and cancer cells. Peptides 24:163–177

    Article  PubMed  CAS  Google Scholar 

  • Oberndorfer S (1907) Karzinoide tumoren des dünndarms. Frankf Z Pathol 1:426–429

    Google Scholar 

  • Ohta H, Yamamoto K, Endo K, Mori T, Hamanaka D, Shimazu A, Ikekubo K, Makimoto K, Iida Y, Konishi J et al (1984) A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 25:323–325

    PubMed  CAS  Google Scholar 

  • Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A, Langstrom B, Oberg K, Eriksson B (1998) Positron emission tomography with 5-hydroxytry-prophan in neuroendocrine tumors. J Clin Oncol 16:2534–2541

    PubMed  CAS  Google Scholar 

  • Otte A, Mueller-Brand J, Delias S, Nitzsche EU, Herrmann R, Maecke HR (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417–478

    Article  PubMed  CAS  Google Scholar 

  • Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Müller J (1999) Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26:1439–1447

    Article  PubMed  CAS  Google Scholar 

  • Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F (2001) Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreo-tide. Eur J Nucl Med 28:426–434

    Article  PubMed  CAS  Google Scholar 

  • Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G, Pedrazzoli S (1998) Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22:588–592

    Article  PubMed  CAS  Google Scholar 

  • Pasquali C, Sperti C, Scappin S, Lunardi C, Chierichetti F, Liessi G, Pedrazzoli S (2004) Role and indications of fluorodeoxyglucose positron emission tomography (FDG-PET) in neuroendocrine pancreatico-duode-nal tumors. J Pancreas 6 [5 Suppl]:528–529

    Google Scholar 

  • Pearse AG (1969) The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologie, physiologic and pathologic implications of the concept. J Histochem Cytochem 17:303–313

    PubMed  CAS  Google Scholar 

  • Pershagen G (1998) Environmental epidemiology in public health. Lancet 352:417

    Article  PubMed  CAS  Google Scholar 

  • Raderer M, Pangerl T, Leimer M, Valencak J, Kurtaran A, Hamilton G, Scheithauer W, Virgolini I (1998) Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo. J Natl Cancer Inst 90:1666–1668

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793

    PubMed  CAS  Google Scholar 

  • Reubi JC, Schaer JC, Waser B (1997) Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57:1377–1386

    PubMed  CAS  Google Scholar 

  • Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, Schmidt MA, Bugaj JE (1998) Unsul-fated DTPA-and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 25:481–490

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Gugger M, Waser B, Schaer JC (2001a) Y(l)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61:4636–4641

    PubMed  CAS  Google Scholar 

  • Reubi JC, Waser B, Schaer JC, Laissue JA (2001b) Somatostatin receptor sstl-sst5 expression in normal and neoplastic human tissues using receptor autoradiog-raphy with subtype-selective ligands. Eur J Nucl Med 28:836–846

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA (2000a) Vasoactive intestinal peptide/ pituitary adenylate cydase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60:3105–3112

    PubMed  CAS  Google Scholar 

  • Reubi JC, Schaer JC, Wenger S, Hoeger C, Erchegyi J, Waser B, Rivier J (2000b) SST3-selective potent pep-tidic somatostatin receptor antagonists. Proc Natl Acad Sci USA 97:13973–3978

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR (2000c) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282

    Article  PubMed  CAS  Google Scholar 

  • Reubi C, Gugger M, Waser B (2002) Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 29:855–862

    Article  PubMed  CAS  Google Scholar 

  • Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36:228–247

    Article  PubMed  Google Scholar 

  • Scanga DR, Martin WH, Delbeke D (2004) Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 29:86–90

    Article  PubMed  Google Scholar 

  • Schmitt-Gräff A, Hezel B, Wiedenmann B (2000) Pathologisch-diagnostische Aspekte neuroendokriner tumoren des Gastrointestinal trakts. Onkologe 6:613–623

    Article  Google Scholar 

  • Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585

    PubMed  CAS  Google Scholar 

  • Shapiro B, Fig LM, Gross MD, Khafagi F (1989) Radio-chemical diagnosis of adrenal disease. Crit Rev Clin Lab Sci 27:265–298

    Article  PubMed  CAS  Google Scholar 

  • Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513–521

    Article  PubMed  CAS  Google Scholar 

  • Solcia E, Klöppel G, Sobin LH (2000) Histological typing of tumors. International Histological Classification of Tumors in collaboration with 9 pathologists from 4 countries (WH OP PW H. Organisation, ed.) Springer, Berlin New York Heidelberg

    Google Scholar 

  • Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C (1998) The somatostatin receptor-targeted radiotherapeutic [ Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 25:668–674

    Article  PubMed  CAS  Google Scholar 

  • Sundin A, Eriksson B, Bergstrom M, Langstrom B, Oberg K, Orlefors H (2004) PET in the diagnosis of neuroen-docrine tumors. Ann NY Acad Sci 1014:246–257

    Article  PubMed  CAS  Google Scholar 

  • Takekawa H, Shinano H, Tsukamoto E, Koseki Y, Ikeno T, Miller F, Kawakami Y (1999) Technetium-99m-tet-rofosmin imaging of lung cancer: relationship with histopathology. Ann Nucl Med 13:71–75

    Article  PubMed  CAS  Google Scholar 

  • Thakur ML, Marcus CS, Saeed S, Pallela V, Minami C, Diggles L, Le Pham H, Ahdoot R, Kalinowski EA (2000) 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med 41:107–110

    PubMed  CAS  Google Scholar 

  • Van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, Laissue J, Waser B, Lamberts SW, Visser TJ, Krenning EP (1996) Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 23:1508–1513

    Article  PubMed  Google Scholar 

  • Virgolini I (2000) Peptide imaging. Springer, Berlin New York Heidelberg

    Google Scholar 

  • Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N EnglJ Med 331:1116–1121

    Article  CAS  Google Scholar 

  • Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P et al (1995) Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 36:1732–1739

    PubMed  CAS  Google Scholar 

  • Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P (1996) 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 23:685–692

    Article  PubMed  CAS  Google Scholar 

  • Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P (1998) Indium-lll-DOTA-lanreotide: biodistribu-tion, safety and radiation absorbed dose in tumor patients. J Nucl Med 39:1928–1936

    PubMed  CAS  Google Scholar 

  • Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J (2002) Tumor response and clinical benefit in neu-roendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610–616

    PubMed  CAS  Google Scholar 

  • Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ (2003) Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 63:6864–6869

    PubMed  CAS  Google Scholar 

  • Weiner RE, Thakur ML (2002) Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 57:749–763

    Article  PubMed  CAS  Google Scholar 

  • Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2:3 and 5 for labelling with various radio-metals. Eur J Nucl Med Mol Imaging 30:1338–1347

    Article  PubMed  CAS  Google Scholar 

  • Zhao DS, Valdivia AY, Li Y, Blaufox MD (2002) 18F-fluo-rodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 32:272–275

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentralklinik Bad Berka GmbH, Nuklearmedizinische Klinik, Robert-Koch-Allee 9, 99437, Bad Berka, Germany

    Prof. Dr. med. R. P. Baum

  2. Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437, Bad Berka, Germany

    Dr. med. V. Prasad

  3. Zentralklinik Bad Berka GmbH, Klinik für Allgemeine Chirurgie/Viszeralchirurgie, Robert-Koch-Allee 9, 99437, Bad Berka, Germany

    Dr. med. M. Hommann

  4. Zentralklinik Bad Berka GmbH, Klinik für Innere Medizin/NET-Zentrum, Robert-Koch-Allee 9, 99437, Bad Berka, Germany

    Dr. med. D. Hörsch

Authors
  1. Prof. Dr. med. R. P. Baum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. V. Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. med. M. Hommann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr. med. D. Hörsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Nuklearmedizin, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany

    Stefan Dresel

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Baum, R.P., Prasad, V., Hommann, M., Hörsch, D. (2008). Receptor PET/CT Imaging of Neuroendocrine Tumors. In: Dresel, S. (eds) PET in Oncology. Recent Results in Cancer Research, vol 170. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31203-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-31203-1_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31202-4

  • Online ISBN: 978-3-540-31203-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation